Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Thoracic 3Genitourinary 3Gynecologic 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Brain Neoplasms 7Carcinoma, Renal Cell 4Glioblastoma 3Central Nervous System Neoplasms 3Carcinoma, Medullary 3Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Pheochromocytoma 2Paraganglioma 2Osteosarcoma 2Neurofibroma, Plexiform 2Glioma 2Astrocytoma 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Rhabdoid Tumor 1Paraganglioma, Extra-Adrenal 1Neurofibromatosis 1 1Neurofibromatoses 1Neuroendocrine Tumors 1Neuroblastoma 1Meningioma 1Melanoma 1Lung Neoplasms 1Hepatoblastoma 1

Interventions

pembrolizumab 3Trastuzumab 2Irinotecan 2Cyclophosphamide 2vocimagene amiretrorepvec 1veliparib 1sacituzumab govitecan 1paclitaxel-Angiopep-2 conjugate 1lenvatinib 1irinotecan sucrosofate 1iniparib 1fludarabine 1depatuxizumab mafodotin 1cabozantinib 1bintrafusp alfa protein, human 1aldesleukin 1Platinum 1Nivolumab 1NVP-BKM120 1N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide 1Metformin 1Mebendazole 1Ipilimumab 1Interleukin-2 1Flucytosine 1Doxycycline 1Cisplatin 1Capecitabine 1Atorvastatin 17-hydroxystaurosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × cabozantinib × CNS × Clear all
NCT02260531 2021-05-20

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Dana-Farber Cancer Institute

Phase 2 Completed
36 enrolled 19 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡